Our top pick for
Building a portfolio
ADMA Biologics, Inc is a biotechnology business based in the US. ADMA Biologics shares (ADMA) are listed on the NASDAQ and all prices are listed in US Dollars. ADMA Biologics employs 406 staff and has a trailing 12-month revenue of around USD$42.2 million.
|52-week range||USD$1.57 - USD$4.2|
|50-day moving average||USD$2.1414|
|200-day moving average||USD$2.1821|
|Wall St. target price||USD$8.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.243|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$42.2 million|
|Gross profit TTM||USD$-11,571,643|
|Return on assets TTM||-21.44%|
|Return on equity TTM||-132.38%|
|Market capitalisation||USD$217.1 million|
TTM: trailing 12 months
There are currently 8.5 million ADMA Biologics shares held short by investors – that's known as ADMA Biologics's "short interest". This figure is 4.4% up from 8.2 million last month.
There are a few different ways that this level of interest in shorting ADMA Biologics shares can be evaluated.
ADMA Biologics's "short interest ratio" (SIR) is the quantity of ADMA Biologics shares currently shorted divided by the average quantity of ADMA Biologics shares traded daily (recently around 3.0 million). ADMA Biologics's SIR currently stands at 2.89. In other words for every 100,000 ADMA Biologics shares traded daily on the market, roughly 2890 shares are currently held short.
However ADMA Biologics's short interest can also be evaluated against the total number of ADMA Biologics shares, or, against the total number of tradable ADMA Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADMA Biologics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ADMA Biologics shares in existence, roughly 80 shares are currently held short) or 0.1049% of the tradable shares (for every 100,000 tradable ADMA Biologics shares, roughly 105 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ADMA Biologics.
Find out more about how you can short ADMA Biologics stock.
We're not expecting ADMA Biologics to pay a dividend over the next 12 months.
Over the last 12 months, ADMA Biologics's shares have ranged in value from as little as $1.57 up to $4.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ADMA Biologics's is 1.3155. This would suggest that ADMA Biologics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.